title: Immunization with a peptide of Semliki Forest virus promotes remyelination in experimental autoimmune encephalomyelitis.
abstract: Remyelination is one of the elusive topics in treatment of multiple sclerosis (MS). Our previous studies have shown that Semliki Forest virus (SFV)-infected δ-knock-out (KO) mice did not exhibit the extensive remyelination, seen in wild type (WT) B6 mice, after viral clearance and demyelination. The Remyelination in SFV-infected WT mice started on day 15 and was completed by day 35 post-infection (pi), whereas the KO mice remained partially demyelinated through day 42 pi. Treatment with E2 peptide2 in incomplete Freund's adjuvant (IFA), resulted in higher antibody production and earlier remyelination in SFV-infected KO (day 28 pi), than WT mice. This finding suggested that anti-E2 peptide2 antibody could play a part in remyelination. In the current study, the effect of E2 peptide2 treatment was evaluated in the experimental autoimmune encephalomyelitis (EAE) model. Mice with established EAE were treated with E2 peptide2 in IFA to develop antibody. Treated EAE mice made significantly higher anti-E2 peptide2 antibody than untreated EAE group. Average clinical disease scores were significantly lower in peptide treated compared to untreated EAE mice. Furthermore, histopathological and immunohistochemical studies demonstrated increased remyelinating areas and higher number of activated oligodendrocytes and astrocytes, in treated compared to untreated EAE groups. Moreover, the anti-E2 peptide2 antibody showed higher binding to the myelinated areas of treated than untreated EAE mice. We conclude that treatment with, or antibody to, SFV E2 peptide2 triggers some mechanism that promotes remyelination.
authors.affiliation: Department of Cell Biology, SUNY Downstate, USA; Department of Neurology, SUNY Stony Brook, USA. fmokhtarianSUNY@aol.com
authors.forename: Foroozan
authors.initials: F
authors.lastname: Mokhtarian
authors.forename: Farinaz
authors.initials: F
authors.lastname: Safavi
authors.forename: Ehsan
authors.initials: E
authors.lastname: Sarafraz-Yazdi
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D001253:Astrocytes / Q000276:immunology / Q000473:pathology; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D005260:Female; D007114:Immunization; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009103:Multiple Sclerosis / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009186:Myelin Sheath / Q000276:immunology / Q000473:pathology; D063308:Myelin-Oligodendrocyte Glycoprotein / Q000276:immunology; D009416:Nerve Regeneration / Q000187:drug effects* / Q000276:immunology; D009836:Oligodendroglia / Q000276:immunology / Q000473:pathology; D010455:Peptides / Q000276:immunology* / Q000494:pharmacology; D012672:Semliki forest virus / Q000276:immunology*; D013116:Spinal Cord / Q000276:immunology / Q000473:pathology
chemical_list: D000914:Antibodies, Viral; C571327:Mog protein, mouse; D063308:Myelin-Oligodendrocyte Glycoprotein; D010455:Peptides